Business Wire

MA-VERACODE

23.5.2023 17:27:28 CEST | Business Wire | Press release

Share
Veracode Named a Leader in the Magic Quadrant™ Application Security Testing For 10th Consecutive Time

Veracode, a leading provider of intelligent software security solutions, has been positioned as a 10-time Leader in the 2023 Gartner Inc. Magic Quadrant for Application Security Testing—an in-depth evaluation of the market’s competitors. The company has been recognized as a Leader in the report every single time since it was first published.

With independent feedback and ratings from customer reviews culminating in a 97 percent “willingness to recommend” (based on 61 reviews, as of 31 July 2022), Veracode was also positioned as a Gartner Peer Insights™ Customers’ Choice for Application Security Testing.

Sam King, Chief Executive Officer at Veracode, said, “For more than 17 years, we have had an unrelenting commitment to making secure software a competitive advantage for our customers. Our continued position as a Leader in the Gartner Magic Quadrant, combined with our recognition as a Customers’ Choice, we feel demonstrates the trust placed in us every day by developers, security teams, and business leaders worldwide. We are proud to say that Veracode was one of the pioneers of application security and now we are propelling the category into the future: intelligent software security.”

The Head of Application Security at a banking company reviewing Veracode in Gartner Peer Insights™ said, “Of all the companies that carry out POCs (Proof of Concepts)...only Veracode proves to be a solid and senior company or enough to put in our financial institution." A security analyst at another firm commented, “In order for a product to be successful, it needs to do two things right, ‘product performance’ and ‘support’. Veracode gives you the best of both worlds, a great product with great support.”

Protecting the Software Supply Chain

Veracode offers EU and UK Support through its dedicated European Region, an EU instance that allows European organizations to address data residency concerns. The company has also achieved the US Federal Risk and Authorization Management Program (FedRAMP), which makes multiple tools available to US federal agencies that want to find and fix software supply chain vulnerabilities in accordance with compliance mandates. Veracode is the only software composition analysis vendor listed in the FedRAMP marketplace.

King said, “Increased reliance on third-party code, along with emerging regulations for software security and data compliance, are some of our customers’ greatest challenges. To alleviate the pressure on organizations, our proprietary database tracks open-source risk and our platform provides continuous scanning through multiple tools, including container security, infrastructure-as-code (IaC) scanning, and Software Bill of Materials (SBOM) capabilities.”

Veracode’s recent addition of Peer Benchmarking—a new self-service capability that allows organizations to measure their flaw and remediation performance against industry peers—also enables security leaders to assess the impact of their investments and demonstrate value to the business.

Strength of Vision: Delivering Capabilities Against Customer Needs

In the past year, Veracode has also made two significant acquisitions, to which the company credits its position in the report. Firstly, the acquisition of the Germany-based Crashtest Security tool enhanced Veracode’s existing dynamic analysis and penetration testing capabilities for web apps and application programming interfaces (APIs), as well as broadening customer access globally. More recently, the acquisition of auto-remediation technology from Jaroona, a 2021 Gartner® Cool Vendor™ for DevSecOps, enabled the launch of Veracode Fix. The new AI-powered product automatically suggests remediations for security flaws found in code and open-source dependencies.

Brian Roche, Chief Product Officer at Veracode, said, “One of the biggest pain points our customers express is mitigating intensifying threat against an expanding attack surface, while accelerating development velocity and minimizing costs. We’ve invested heavily in our platform over the past year to develop automated solutions that remove friction for developers and provide security teams with a comprehensive view of risk. The launch of Veracode Fix addresses the need to broaden our focus from application security testing to intelligent software security.”

To download a complimentary copy of the full 2023 Gartner Magic Quadrant Report, visit the Veracode website.

To learn more about intelligent software security from Veracode, please visit: https://www.veracode.com/products

1Gartner, Magic Quadrant for Application Security Testing, Mark Horvath, Dale Gardner, Manjunath Bhat, Ravisha Chugh, Angela Zhao, 17 May 2023.

2Gartner, “Peer Insights ‘Voice of the Customer’: Application Security Testing” by Peer Contributors, September 30, 2022.

Gartner does not endorse any vendor, product or service depicted in our research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

Gartner Peer Insights content consists of the opinions of individual end users based on their own experiences, and should not be construed as statements of fact, nor do they represent the views of Gartner or its affiliates. Gartner does not endorse any vendor, product or service depicted in this content nor makes any warranties, expressed or implied, with respect to this content, about its accuracy or completeness, including any warranties of merchantability or fitness for a particular purpose.

GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally, Magic Quadrant, Cool Vendors and PEER INSIGHTS are registered trademarks of Gartner, Inc. and/or its affiliates and are used herein with permission. All rights reserved.

About Veracode

Veracode is intelligent software security. The Veracode Software Security Platform continuously finds flaws and vulnerabilities at every stage of the modern software development lifecycle. Prompted by powerful AI trained by trillions of lines of code, Veracode customers fix flaws faster with high accuracy. Trusted by security teams, developers, and business leaders from thousands of the world’s leading organizations, Veracode is the pioneer, continuing to redefine what intelligent software security means.

Copyright © 2023 Veracode, Inc. All rights reserved. Veracode is a registered trademark of Veracode, Inc. in the United States and may be registered in certain other jurisdictions. All other product names, brands or logos belong to their respective holders. All other trademarks cited herein are property of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230523005707/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release

Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa

EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release

EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia

Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release

Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting

FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release

FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease

Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release

Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye